帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
英文原题:Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy.
Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy.
LAG3、TIM3 和 TPS 是接受(放化疗)放疗的老年 HNSCC 患者中有前景的生物标志物。考虑到该人群中非癌症相关死亡的发生频率,这些生物标志物的预后价值主要与 LRC 相关。
TIL(肿瘤浸润淋巴细胞)(TILs)与接受(放)化疗的头颈部鳞状细胞癌(HNSCC)患者的局部区域控制(LRC)相关。由于免疫衰老导致免疫活性降低,TILs在老年HNSCC患者中的作用可能与年轻患者不同,这为研究TILs和免疫检查点(ICs)在该人群中的预后作用提供了依据。
分析纳入了63例年龄65岁、于2010年至2019年间接受根治性(放)化疗且治疗前活检材料充足的HNSCC患者。进行了CD3、CD4、CD8、PD-L1、TIM3、LAG3、TIGIT和CD96的免疫组化染色,以及作为免疫衰老相关蛋白的骨桥蛋白染色。使用Kaplan-Meier法确定总生存期(OS)和无进展生存期(PFS),并使用Fine-Gray模型进行局部区域失败(LRF)分析。
患者年龄与 IC 表达之间无相关性,而骨桥蛋白水平与年龄增长相关(r = 0.322,p < 0.05)。2 年 OS、PFS 和 LRC 分别为 44%、34% 和 71%。LAG3 表达升高,无论是上皮内(SHR = 0.33,p < 0.05)还是间质中(SHR = 0.38,p < 0.05),以及间质 TIM3 表达升高(SHR = 0.32,p < 0.05),均与 LRF 降低相对应。肿瘤 PD-L1 表达缺失(TPS = 0%)与更多 LRF 相关(SHR = 0.28,p < 0.05)。在上皮内 CD3 +(SHR = 0.52,p = 0.07)和 CD8 +(SHR = 0.52,p = 0.09)TIL 水平升高的老年患者中,LRF 率有改善趋势。
BACKGROUND AND PURPOSE: Tumor-infiltrating lymphocytes (TILs) are associated with locoregional control (LRC) in head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy. As immunosenescence results in reduced immune activity, the role of TILs in elderly HNSCC patients may differ compared to younger patients, providing a rationale to study the prognostic role of TILs and immune checkpoints (ICs) in this population. MATERIAL AND METHODS: Sixty-three HNSCC patients aged 65 years undergoing definitive (chemo)radiotherapy between 2010 and 2019 with sufficient material from pre-treatment biopsies were included in the analysis. Immunohistochemical stainings of CD3, CD4, CD8, PD-L1, TIM3, LAG3, TIGIT and CD96, and of osteopontin as an immunosenescence-associated protein were performed. Overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method, and Fine-Gray's models were used for locoregional failure (LRF) analyses. RESULTS: While there was no correlation between patient age and IC expression, osteopontin levels correlated with increasing age (r = 0.322, p < 0.05). Two-year OS, PFS, and LRC were 44%, 34%, and 71%, respectively. Increased LAG3 expression, both intraepithelial (SHR = 0.33, p < 0.05) and stromal (SHR = 0.38, p < 0.05), and elevated stromal TIM3 expression (SHR = 0.32, p < 0.05) corresponded with reduced LRFs. Absent tumoral PD-L1 expression (TPS = 0%) was associated with more LRFs (SHR = 0.28, p < 0.05). There was a trend towards improved LRF rates in elderly patients with increased intraepithelial CD3 + (SHR = 0.52, p = 0.07) and CD8 + (SHR = 0.52, p = 0.09) TIL levels. CONCLUSION: LAG3, TIM3 and TPS are promising biomarkers in elderly HNSCC patients receiving (chemo)radiotherapy. Considering the frequency of non-cancer related deaths in this population, the prognostic value of these biomarkers primarily relates to LRC.
MEMBER ACCOUNT
登录成功会直接打开下一页。